Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

被引：0

作者：

Pleyer, Lisa ^{[1
,2
]}

Burgstaller, Sonja ^{[3
]}

Stauder, Reinhard ^{[4
]}

Girschikofsky, Michael ^{[5
]}

Linkesch, Werner ^{[6
]}

Pfeilstoecker, Michael ^{[7
]}

Autzinger, Eva Maria ^{[8
]}

Tinchon, Christoph ^{[9
]}

Sliwa, Thamer ^{[7
]}

Lang, Alois ^{[10
]}

Sperr, Wolfgang R. ^{[11
]}

Geissler, Dietmar ^{[12
]}

Krippl, Peter ^{[13
]}

Voskova, Daniela ^{[14
]}

Rossmann, Dieter H. ^{[15
]}

Schlick, Konstantin ^{[16
]}

Thaler, Josef ^{[3
]}

Halter, Britta ^{[4
]}

Machherndl-Spandl, Sigrid ^{[5
]}

Theiler, Georg ^{[17
]}

Valent, Peter ^{[11
]}

Eckmuellner, Otto ^{[18
]}

Greil, Richard ^{[1
,19
]}

机构：

[1] Paracelsus Med Univ Salzburg, Salzburg, Austria

[2] Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials, Salzburg, Austria

[3] Klinikum Wels Grieskirchen, Wels, Austria

[4] Med Univ Innsbruck, A-6020 Innsbruck, Austria

[5] Elisabethinen Hosp, Linz, Austria

[6] Med Univ Graz, Graz, Austria

[7] Hanusch Hosp, Vienna, Austria

[8] Wilhelminenspital Stadt Wien, Vienna, Austria

[9] LKH Leoben, Leoben, Austria

[10] LKH Rankweil, Rankweil, Austria

[11] Med Univ Vienna, Vienna, Austria

[12] Klinikum Klagenfurt, Klagenfurt, Austria

[13] LKH Furstenfeld, Furstenfeld, Austria

[14] Gen Hosp Linz, Linz, Austria

[15] Hosp Steyr, Steyr, Austria

[16] PMU, Salzburg, Austria

[17] LKH Hartberg, Hartberg, Austria

[18] Forest Growth, Vienna, Austria

[19] Salzburg Canc Res Inst, Salzburg, Austria

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[21] Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Bouvier, Anne
Hamel, Jean-Francois
Delaunay, Jacques
Delabesse, Eric
Dumas, Pierre-Yves
Ledoux, Marie-Pierre
Peterlin, Pierre
Luquet, Isabelle
Roth Guepin, Gabrielle
Bulabois, Claude Eric
Gallego Hernanz, Maria Pilar
Guillerm, Gaelle
Guieze, Romain
Hicheri, Yosr
Simand, Celestine
Himberlin, Chantal
Hunault-Berger, Mathilde
Bernard, Marc
Jourdan, Eric
Caillot, Denis
Dorvaux, Veronique
Tavernier, Emmanuelle
Daguindau, Etienne
Banos, Anne
Ojeda-Uribe, Mario
Gyan, Emmanuel
Alexis, Magda
Marolleau, Jean-Pierre
Turlure, Pascal
Bouscary, Didier
Humbrecht, Catherine
Zerazhi, Hacene
Bene, Marie-Christine
Pigneux, Arnaud
Carre, Martin
Ifrah, Norbert
Blanchet, Odile
Vey, Norbert
Recher, Christian
Cornillet-Lefebvre, Pascale
EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (01) : 111 - 121
[22] Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics
Talati, Chetasi
Kuykendall, Andrew
Al-Ali, Najla
Komrokji, Rami
Padron, Eric
Sallman, David
List, Alan
Sweet, Kendra
Extermann, Martine
Lancet, Jeffrey
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S295 - S295
[23] Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
Tan, P.
Wei, A.
Mithraprabhu, S.
Cummings, N.
Liu, H. B.
Perugini, M.
Reed, K.
Avery, S.
Patil, S.
Walker, P.
Mollee, P.
Grigg, A.
D'Andrea, R.
Dear, A.
Spencer, A.
BLOOD CANCER JOURNAL, 2014, 4 : e170 - e170
[24] Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome
P Tan
A Wei
S Mithraprabhu
N Cummings
H B Liu
M Perugini
K Reed
S Avery
S Patil
P Walker
P Mollee
A Grigg
R D'Andrea
A Dear
A Spencer
Blood Cancer Journal, 2014, 4 : e170 - e170
[25] Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
Yu, Sijian
Fan, Zhiping
Ma, Liping
Wang, Yu
Huang, Fen
Zhang, Qing
Huang, Jiafu
Wang, Shunqing
Xu, Na
Xuan, Li
Xiong, Mujun
Han, Lijie
Sun, Zhiqiang
Zhang, Hongyu
Liu, Hui
Yu, Guopan
Shi, Pengcheng
Xu, Jun
Wu, Meiqing
Guo, Ziwen
Xiong, Yiying
Duan, Chongyang
Sun, Jing
Liu, Qifa
Zhang, Yu
JAMA NETWORK OPEN, 2021, 4 (07)
[26] RESPONSE TO 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASIC SYNDROME, CHRONIC MYELOMONOCYTIC LEUKEMIA, AND ACUTE MYELOID LEUKEMIA WITH HIGH-RISK GENETICS
Perez Ortega, L.
Falantes Gonzalez, J. F.
Moya Arnau, M.
Perez Simon, J. A.
HAEMATOLOGICA, 2019, 104 : 293 - 294
[27] Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia
Linch, David C.
Hills, Robert K.
Burnett, Alan K.
Khwaja, Asim
Gale, Rosemary E.
BLOOD, 2014, 124 (02) : 273 - 276
[28] Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children A Review
Ross, Catherine
Kumar, Riten
Pelland-Marcotte, Marie-Claude
Mehta, Shivani
Kleinman, Monica E.
Thiagarajan, Ravi R.
Ghbeis, Muhammad B.
VanderPluym, Christina J.
Friedman, Kevin G.
Porras, Diego
Fynn-Thompson, Francis
Goldhaber, Samuel Z.
Brandao, Leonardo R.
CHEST, 2022, 161 (03) : 791 - 802
[29] Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia
Cressman, Sonya
Karsan, Aly
Hogge, Donna E.
McPherson, Emily
Bolbocean, Corneliu
Regier, Dean A.
Peacock, Stuart J.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (04) : 526 - 535
[30] SINGLE CENTRE SURVIVAL OUTCOMES IN THE TREATMENT OF INTERMEDIATE AND HIGH-RISK MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKAEMIA WITH 5-AZACITIDINE
Stringer, R.
Rider, D. T.
Newman, D. J.
Grace, D. R.
HAEMATOLOGICA, 2015, 100 : 725 - 726

← 1 2 3 4 5 →